Novel Oral Anticoagulants (NOAC) Market By Type ( Direct Thrombin Inhibitors, Direct Factor Xa Inhibitors ), By Application ( Deep Vein Thrombosis (DVT), Pulmonary Embolism, Acute Coronary Syndrome, Hemodialysis ), Industry Trends, Estimation & Forecast, 2017 - 2025

Check Today's Best Price

$3500 Buy Now
Novel Oral Anticoagulants (NOAC) Market is expected to grow with a CAGR of xx% during the forecast period of 2018 to 2025.
  • Market Overview:

    Anticoagulants are the chemical substances which help in preventing the blood from clotting. Blood clots are very helpful in stop bleeding from wounds, but, if they get dislodged from another site and merge in the blood circulation, they can also block the blood vessels and stop the blood flow to different organs of the body, causing strokes, heart attacks, and even death. Anticoagulants work as a blood thinner and are now being frequently used for the patients suffering from thromboembolism. Initially, drugs such as warfarin, which is a vitamin K antagonist, were used as the only oral substitute of anticoagulants. The presence of a few limitations such as need for frequent laboratory monitoring and serious side effects, compelled the medical authorities to come up with a more advanced and relevant medicinal substitute of warfarin.

    Novel Oral Anticoagulants (NOACs) have emerged out as a new and enhanced medication with potential benefits, which could be administered to the patients dealing with pulmonary disorders and thromboembolism without frequent monitoring. These medicines have very slight intra-patient variations and the dosing is least patient specific as compared to warfarin. However, increased risk of excessive bleeding and adverse gastrointestinal disorders might act as a major restraining factor for the growth of the market. However, its increasing adoption in the regions such as North America, as a result of constantly rising cases of thromboembolism will act as a major opportunity for the market growth. As per a survey, nearly 7% of the total U.S. population is having inherited thrombophilia, which can seriously increase the chances of thrombosis within them.
    The report provides detailed qualitative and quantitative analysis of the Global Novel Oral Anticoagulants (NOAC) Market. Market size and forecast in terms of value and volume has been provided for the period – (2017 – 2025), for the segments namely type and application in each of the major regions.

    Novel Oral Anticoagulants (NOAC) Market Segmentation

    By Type
    • Direct Thrombin Inhibitors
    • Direct Factor Xa Inhibitors

    By Application
    • Deep Vein Thrombosis (DVT)
    • Pulmonary Embolism
    • Acute Coronary Syndrome
    • Hemodialysis
    • Others

    By Geography

    • North America
    o U.S.
    o Canada
    o Mexico

    • Europe
    o U.K.
    o France
    o Germany
    o Italy
    o Spain
    o Rest of Europe

    • Asia-Pacific
    o China
    o Japan
    o India
    o Korea
    o Rest of APAC

    • South America
    o Brazil
    o Rest of South America

    • Rest of the World
    o Middle East
    o Africa

    keyboard_arrow_up
  • CHAPTER 1. INTRODUCTION
    1.1. RESEARCH METHODOLOGY
    1.1.1. ERC desk research
    1.1.2. ERC data synthesis
    1.1.3. Data validation and market feedback
    1.1.4. ERC data sources

    CHAPTER 2. NOVEL ORAL ANTICOAGULANTS (NOAC) MARKET OVERVIEW
    2.1. NOVEL ORAL ANTICOAGULANTS (NOAC) MARKET INTRODUCTION
    2.2. GLOBAL NOVEL ORAL ANTICOAGULANTS (NOAC) MARKET PRODUCTION AND GROWTH RATE, 2017-2025
    2.2.1. Global Novel Oral Anticoagulants (NOAC) Production (VOLUME) and Growth Rate (%), (2017-2025)
    2.3. GLOBAL NOVEL ORAL ANTICOAGULANTS (NOAC) MARKET CAPACITY AND GROWTH RATE, 2017-2025
    2.3.1. Global Novel Oral Anticoagulants (NOAC) Capacity (VOLUME) and Growth Rate (%), (2017-2025)
    2.4. GLOBAL NOVEL ORAL ANTICOAGULANTS (NOAC) MARKET REVENUE AND GROWTH RATE, 2017-2025
    2.4.1. Global Novel Oral Anticoagulants (NOAC) Market Revenue (Million USD) and Growth Rate (%), (2017-2025)
    2.5. GLOBAL NOVEL ORAL ANTICOAGULANTS (NOAC) MARKET CONSUMPTION AND GROWTH RATE, 2017-2025
    2.5.1. Global Novel Oral Anticoagulants (NOAC) Consumption (VOLUME) and Growth Rate (%), (2017-2025)
    2.6. GLOBAL NOVEL ORAL ANTICOAGULANTS (NOAC) MARKET PRICE TREND, 2017-2025
    2.6.1. Global Novel Oral Anticoagulants (NOAC) Market Price Trend and Growth Rate (%), (2017-2025)

    CHAPTER 3. GLOBAL NOVEL ORAL ANTICOAGULANTS (NOAC) MARKET BY TYPE, 2017-2025
    3.1. DIRECT THROMBIN INHIBITORS
    3.2. DIRECT FACTOR XA INHIBITORS
    3.3. GLOBAL NOVEL ORAL ANTICOAGULANTS (NOAC) MARKET REVENUE BY TYPE, 2017-2025
    3.3.1. Global Novel Oral Anticoagulants (NOAC) Market Revenue (Million USD) and Share (%) By Type, 2017-2025
    3.3.2. Direct Thrombin Inhibitors Market Revenue and Growth Rate, 2017-2025
    3.3.3. Direct Factor Xa Inhibitors Market Revenue and Growth Rate, 2017-2025
    3.4. GLOBAL NOVEL ORAL ANTICOAGULANTS (NOAC) MARKET PRODUCTION BY TYPE, 2017-2025
    3.4.1. Global Novel Oral Anticoagulants (NOAC) Market Production (Volume) and Share (%) By Type, 2017-2025
    3.4.2. Direct Thrombin Inhibitors Market Production and Growth Rate, 2017-2025
    3.4.3. Direct Factor Xa Inhibitors Market Production and Growth Rate, 2017-2025

    CHAPTER 4. GLOBAL NOVEL ORAL ANTICOAGULANTS (NOAC) MARKET BY APPLICATION, 2017-2025
    4.1. DEEP VEIN THROMBOSIS (DVT)
    4.2. PULMONARY EMBOLISM
    4.3. ACUTE CORONARY SYNDROME
    4.4. GLOBAL NOVEL ORAL ANTICOAGULANTS (NOAC) MARKET REVENUE BY APPLICATION, 2017-2025
    4.4.1. Global Novel Oral Anticoagulants (NOAC) Market Revenue (Million USD) and Share (%) By Application, 2017-2025
    4.4.2. Deep Vein Thrombosis (DVT) Market Revenue and Growth Rate, 2017-2025
    4.4.3. Pulmonary Embolism Market Revenue and Growth Rate, 2017-2025
    4.4.4. Acute Coronary Syndrome Market Revenue and Growth Rate, 2017-2025
    4.5. GLOBAL NOVEL ORAL ANTICOAGULANTS (NOAC) MARKET CONSUMPTION BY APPLICATION, 2017-2025
    4.5.1. Global Novel Oral Anticoagulants (NOAC) Market Consumption (Volume) and share (%) By Application, 2017-2025
    4.5.2. Deep Vein Thrombosis (DVT) Market Consumption and Growth Rate, 2017-2025
    4.5.3. Pulmonary Embolism Market Consumption and Growth Rate, 2017-2025
    4.5.4. Acute Coronary Syndrome Market Consumption and Growth Rate, 2017-2025

    Note: Similar information coverage has been provided for other application segment.

    CHAPTER 5. GLOBAL NOVEL ORAL ANTICOAGULANTS (NOAC) MARKET BY REGION, 2017-2025
    5.1. NORTH AMERICA
    5.1.1. U.S.
    5.1.2. Canada
    5.1.3. Mexico
    5.2. EUROPE
    5.2.1. U.K.
    5.2.2. France
    5.2.3. Germany
    5.2.4. Italy
    5.2.5. Spain
    5.2.6. Rest of Europe
    5.3. ASIA PACIFIC
    5.3.1. China
    5.3.2. Japan
    5.3.3. India
    5.3.4. Korea
    5.3.5. Rest of APAC
    5.4. SOUTH AMERICA
    5.4.1. Brazil
    5.4.2. Rest of South America
    5.5. REST OF THE WORLD
    5.5.1. Middle East
    5.5.2. Africa
    5.6. GLOBAL NOVEL ORAL ANTICOAGULANTS (NOAC) MARKET REVENUE BY REGION, 2017-2025
    5.6.1. Global Novel Oral Anticoagulants (NOAC) Market Revenue (Million USD) and Share (%) By Region, 2017-2025
    5.6.2. North America Market Revenue and Growth Rate, 2017-2025
    5.6.3. Europe Market Revenue and Growth Rate, 2017-2025
    5.6.4. Asia Pacific Market Revenue and Growth Rate, 2017-2025
    5.6.5. South America Market Revenue and Growth Rate, 2017-2025
    5.6.6. Rest of the World Market Revenue and Growth Rate, 2017-2025

    CHAPTER 6. GLOBAL NOVEL ORAL ANTICOAGULANTS (NOAC) MARKET PRODUCTION AND CONSUMPTION ANALYSIS BY REGION, 2017-2025
    6.1. GLOBAL NOVEL ORAL ANTICOAGULANTS (NOAC) MARKET PRODUCTION ANALYSIS BY REGION, 2017-2025
    6.1.1. Global Novel Oral Anticoagulants (NOAC) Market Production (Volume) and Share (%) By Region, 2017-2025
    6.1.2. Global Novel Oral Anticoagulants (NOAC) Market Consumption (Volume) and Share (%) By Region, 2017-2025
    6.1.3. North America Market Production and Consumption, 2017-2025
    6.1.4. Europe Market Production and Consumption, 2017-2025
    6.1.5. Asia Pacific Market Production and Consumption, 2017-2025
    6.1.6. South America Market Production and Consumption, 2017-2025
    6.1.7. Rest of the World Market Production and Consumption, 2017-2025

    CHAPTER 7. MARKET DETERMINANTS
    7.1. MARKET DRIVERS
    7.2. MARKET RESTRAINTS
    7.3. MARKET OPPORTUNITIES
    7.4. MARKET DETERMINANTS RADAR CHART

    CHAPTER 8. GLOBAL NOVEL ORAL ANTICOAGULANTS (NOAC) MARKET COMPETITION BY MANUFACTURERS
    8.1. GLOBAL NOVEL ORAL ANTICOAGULANTS (NOAC) PRODUCTION AND SHARE BY MANUFACTURERS (2017-2025)
    8.1.1. Global Novel Oral Anticoagulants (NOAC) Production (VOLUME) and Share (%) by Manufacturers (2017-2025)
    8.2. GLOBAL NOVEL ORAL ANTICOAGULANTS (NOAC) REVENUE AND SHARE BY MANUFACTURERS (2017-2025)
    8.2.1. Global Novel Oral Anticoagulants (NOAC) Revenue (Million USD) and Share (%) by Manufacturers (2017-2025)
    8.3. NOVEL ORAL ANTICOAGULANTS (NOAC) MARKET COMPETITIVE SITUATION AND TRENDS
    8.3.1. Novel Oral Anticoagulants (NOAC) Market Share (%) of Top 3 Manufacturers
    8.3.2. Novel Oral Anticoagulants (NOAC) Market Share (%) of Top 5 Manufacturers

    CHAPTER 9. GLOBAL NOVEL ORAL ANTICOAGULANTS (NOAC) MANUFACTURERS ANALYSIS
    9.1. JOHNSON & JOHNSON
    9.1.1. Business Overview
    9.1.2. Company Basic Information
    9.1.3. Novel Oral Anticoagulants (NOAC) Product Details
    9.1.4. Johnson & Johnson Novel Oral Anticoagulants (NOAC) Production, Revenue and Gross Margin
    9.2. BRISTOL-MYERS SQUIBB
    9.2.1. Business Overview
    9.2.2. Company Basic Information
    9.2.3. Novel Oral Anticoagulants (NOAC) Product Details
    9.2.4. Bristol-Myers Squibb Novel Oral Anticoagulants (NOAC) Production, Revenue and Gross Margin
    9.3. BOEHRINGER INGELHEIM
    9.3.1. Business Overview
    9.3.2. Company Basic Information
    9.3.3. Novel Oral Anticoagulants (NOAC) Product Details
    9.3.4. Boehringer Ingelheim Novel Oral Anticoagulants (NOAC) Production, Revenue and Gross Margin
    9.4. SANOFI
    9.4.1. Business Overview
    9.4.2. Company Basic Information
    9.4.3. Novel Oral Anticoagulants (NOAC) Product Details
    9.4.4. Sanofi Novel Oral Anticoagulants (NOAC) Production, Revenue and Gross Margin
    9.5. DAIICHI SANKYO
    9.5.1. Business Overview
    9.5.2. Company Basic Information
    9.5.3. Novel Oral Anticoagulants (NOAC) Product Details
    9.5.4. Daiichi Sankyo Novel Oral Anticoagulants (NOAC) Production, Revenue and Gross Margin
    9.6. ARMATHEON
    9.6.1. Business Overview
    9.6.2. Company Basic Information
    9.6.3. Novel Oral Anticoagulants (NOAC) Product Details
    9.6.4. Armatheon Novel Oral Anticoagulants (NOAC) Production, Revenue and Gross Margin
    9.7. ASPEN
    9.7.1. Business Overview
    9.7.2. Company Basic Information
    9.7.3. Novel Oral Anticoagulants (NOAC) Product Details
    9.7.4. Aspen Novel Oral Anticoagulants (NOAC) Production, Revenue and Gross Margin
    9.8. ASTRAZENECA
    9.8.1. Business Overview
    9.8.2. Company Basic Information
    9.8.3. Novel Oral Anticoagulants (NOAC) Product Details
    9.8.4. Astrazeneca Novel Oral Anticoagulants (NOAC) Production, Revenue and Gross Margin
    9.9. BAYER
    9.9.1. Business Overview
    9.9.2. Company Basic Information
    9.9.3. Novel Oral Anticoagulants (NOAC) Product Details
    9.9.4. Bayer Novel Oral Anticoagulants (NOAC) Production, Revenue and Gross Margin
    9.10. CELLCEUTIX
    9.10.1. Business Overview
    9.10.2. Company Basic Information
    9.10.3. Novel Oral Anticoagulants (NOAC) Product Details
    9.10.4. Cellceutix Novel Oral Anticoagulants (NOAC) Production, Revenue and Gross Margin

    CHAPTER 10. NOVEL ORAL ANTICOAGULANTS (NOAC) MARKET VALUE CHAIN ANALYSIS
    10.1. NOVEL ORAL ANTICOAGULANTS (NOAC) INDUSTRIAL CHAIN ANALYSIS
    10.2. NOVEL ORAL ANTICOAGULANTS (NOAC) KEY RAW MATERIALS ANALYSIS
    10.2.1. Key Raw Materials
    10.2.2. Price Trend of Key Raw Materials
    10.2.3. Key Suppliers of Raw Materials
    10.3. MARKETING CHANNEL
    10.3.1. Direct Marketing
    10.3.2. Indirect Marketing
    10.3.3. Distributors/Traders
    10.4. CONSUMER ANALYSIS
    10.4.1. Consumer 1
    10.4.2. Consumer 2
    10.4.3. Consumer 3
    10.4.4. Consumer 4

    keyboard_arrow_up
    • Johnson & Johnson
    • Bristol-Myers Squibb
    • Boehringer Ingelheim
    • Sanofi
    • Daiichi Sankyo
    • Armatheon
    • Aspen
    • Astrazeneca
    • Bayer
    • Cellceutix
    • Cosmo Pharmaceuticals
    • Csl Behring
    • Eisai
    • Gsk
    • Marathon Pharmaceuticals
    • Ockham Biotech and Perosphere
    keyboard_arrow_up


    • Keep your personal detail safe with us. Privacy Policy
      This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

What Information does this report contain?

• What was the market size of the Novel Oral Anticoagulants (NOAC) Market in 2017 and the expected market size by 2025, along with the growth rate?
• An in-depth analysis of the current impacting factors, opportunities and challenges/restraints in the market
• Which are the largest revenue generating products, services or regions and their comparative growth rate?
• Which technology is in trend and how would it evolve during the forecast period (2017 – 2025)?
• Which are the leading companies in the Novel Oral Anticoagulants (NOAC) Market and their competitive positioning basis their market share, product portfolio, strategic attempts and business focus?

CLIENTS